Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Company PLC

http://www.perrigo.com/

Latest From Perrigo Company PLC

Infant Formula Production Expansion Brings Problems Souring Perrigo's 2024 Forecast

Perrigo doesn’t attempt to diminish significance of challenge to regain sales growth in formula market as it resets its plants. Analysts see formula business as only current impediment to stronger results.

Dietary Supplements Recalls

Perrigo Delivering Opill Sales Within A Month, Launches ‘Energize’ Efficiency Project Immediately

Perrigo says 2024 results will be slowed by investment in companywide efficiency project including staff reductions. After Opill’s expected launch by late March, sales will be dilutive to earnings for the first year partly due to investments in the brand, primarily at retailers and online in Q2.

Women's Health Sales & Earnings

OTC Naloxone Pioneer Emergent BioSolutions Puts Papa At Helm As It Navigates Strategy Shift

Like his previous move, Papa joins a pharma firm making a significant organizational shift to cut costs and increase revenues after extended period of higher spending and slowing income.

Executive Changes OTC Drugs

US Q4 Consumer Health Earnings Preview: Supply Chain Disruption Returns, Opill Launch Waits

Attacks on shipping since November in the Red Sea lead shipping lines to re-route vessels south of Africa, spiking shipping costs. Perrigo began 2024 saying it expects sales of Opill oral contraceptive to start early in the first quarter, but now expects to start late in the quarter.

Consumer Sales & Earnings
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Agis Industries
    • Chemagis
    • Clay-Park Labs
    • Cobrek Pharmaceuticals
    • Elan Corporation
    • JB Laboratories
    • Onclave Therapeutics Limited
    • Omega Pharma Invest N.V.
    • Paddock Laboratories
    • Omega Pharma Invest N.V.
    • Ranir Global Holdings LLC
    • Rosemont Pharmaceuticals Ltd.
    • Unico Holdings Inc.
    • Velcera, Inc.
    • Geiss, Destin & Dunn, Inc.
    • High Ridge Brands
UsernamePublicRestriction

Register